Atopic Dermatitis: Causes, Treatments, and the Hair Loss Connection

What Is Atopic Dermatitis and Who Gets It?

Atopic dermatitis is a chronic relapsing inflammatory skin disease defined by intense pruritus, barrier dysfunction, and a Th2-polarized immune response. It affects approximately 15 to 20% of children and 1 to 10% of adults in high-income countries, with lifetime prevalence continuing to rise. The 2023 Global Burden of Disease analysis estimated 223 million prevalent cases worldwide [1].

The condition clusters with asthma, allergic rhinitis, and food allergy in what clinicians call the "atopic march." Filaggrin gene loss-of-function variants are the most replicated genetic risk factor, found in roughly 30% of European AD patients [2]. Filaggrin encodes a structural protein critical for skin barrier integrity; when it is absent or reduced, trans-epidermal water loss rises, allergen penetration increases, and the local immune response shifts toward Th2 cytokines, especially IL-4 and IL-13 [2].

Diagnosis rests on clinical criteria. The Hanifin and Rajka criteria (1980) and the simplified UK Working Party criteria both require pruritus plus at least three of: flexural involvement, personal history of atopy, dry skin, and onset before age two. No single biomarker replaces clinical assessment, though serum IgE is elevated in roughly 80% of moderate-to-severe cases [3].

Disease severity is graded with validated tools including the Eczema Area and Severity Index (EASI), the Investigator Global Assessment (IGA, 0, 4 scale), and the Patient-Oriented Eczema Measure (POEM). An EASI score above 21 defines severe disease; this threshold was used as an enrollment criterion in the key dupilumab LIBERTY AD SOLO trials [4].

The Immune Mechanism Behind AD: Why It Matters for Treatment Choice

Th2 cytokine dominance is the central driver. IL-4 and IL-13 signal through a shared receptor subunit (IL-4Rα) to suppress filaggrin and loricrin expression, reduce antimicrobial peptide production, and increase IgE synthesis [5]. IL-31 binds its receptor on sensory neurons, directly producing the pruritus that disrupts sleep and quality of life.

Dupilumab targets IL-4Rα and therefore blocks both IL-4 and IL-13 simultaneously. This mechanism explains its broad efficacy across AD, eosinophilic esophagitis, asthma, and chronic rhinosinusitis with nasal polyps. In the LIBERTY AD SOLO 1 and SOLO 2 trials (combined N=1,379), dupilumab 300 mg every two weeks achieved IGA 0 or 1 in 38% of patients at week 16 versus 10% on placebo (P<0.001) [4].

More recent data from the Phase 3 JADE COMPARE trial (N=795) showed upadacitinib 30 mg daily outperformed dupilumab on the co-primary EASI-75 endpoint at week 16: 70.6% versus 60.0% respectively [6]. That head-to-head result drove regulatory interest and physician adoption of JAK inhibitors in patients who have inadequate dupilumab responses.

The HealthRX clinical team uses a three-tier selection framework for moderate-to-severe AD: (1) dupilumab as default first biologic given its long-term safety record across seven-plus years; (2) tralokinumab (IL-13 specific) for patients with dupilumab-associated conjunctivitis; (3) upadacitinib 15 to 30 mg for patients who need faster itch control or who failed dupilumab, with appropriate screening for thrombosis risk, active infection, and malignancy history per the FDA boxed warning issued in 2022 [7].

Topical and Non-Biologic Treatments: The Foundation of AD Care

Topical therapies remain the backbone of AD management at all severity levels. The American Academy of Dermatology (AAD) 2023 guidelines state: "Topical corticosteroids are the first-line anti-inflammatory treatment for patients of all ages with atopic dermatitis and should be used as needed to control flares." [8]

Low-to-mid potency steroids (hydrocortisone 2.5%, triamcinolone 0.1%) are appropriate for facial and intertriginous areas. High-potency agents (clobetasol 0.05%) are reserved for lichenified plaques on the trunk and extremities, limited to two-week courses to reduce atrophy risk. Twice-weekly "proactive" application to previously affected skin reduces relapse rates by approximately 50% compared with reactive-only use in a Cochrane review of 14 trials [9].

Topical calcineurin inhibitors (tacrolimus 0.03% and 0.1%, pimecrolimus 1%) are steroid-sparing options with no skin-atrophy risk, making them useful for the face and skin folds long-term [10]. The FDA approved crisaborole 2% ointment (a PDE4 inhibitor) in 2016 for mild-to-moderate AD in patients age two and older; in the CrisADe CORE 1 and CORE 2 trials (combined N=1,522), 32.8% of crisaborole-treated patients achieved clear or almost-clear skin at day 29 versus 25.4% on vehicle (P<0.001) [11].

Ruxolitinib 1.5% cream, a topical JAK1/JAK2 inhibitor, received FDA approval in 2021 for adolescents and adults with mild-to-moderate AD. In the TRuE-AD1 and TRuE-AD2 trials (combined N=1,249), 53.8% of patients in the ruxolitinib 1.5% group achieved IGA 0/1 at week 8 versus 15.1% on vehicle [12]. Systemic absorption is low at approved doses, limiting the safety concerns associated with oral JAK inhibitors.

Wet wrap therapy applied over topical corticosteroids can reduce EASI scores by 71% in hospitalized patients with severe flares, per a multicenter Dutch study of 20 adults [13]. Phototherapy with narrowband UVB (311, 313 nm) three times weekly achieves EASI-50 in 60 to 70% of patients at 12 weeks and remains an option when biologics are inaccessible [14].

Atopic Dermatitis and Hair Loss: Understanding the Overlap

AD and hair loss disorders share Th2 immune pathways. Patients with AD have a 2.6-fold higher odds of alopecia areata (AA) compared with controls in a population-based Danish cohort of 11,426 AD patients [15]. This association is not coincidental. Both diseases involve dysregulated T-cell activity and loss of immune privilege in the hair follicle bulb.

Alopecia areata is an autoimmune condition in which CD8+ T cells collapse immune privilege at the hair follicle, causing non-scarring patchy hair loss. JAK inhibitors, originally adopted in AD, have become the leading systemic treatment for severe AA. Baricitinib 2 mg daily received FDA approval in June 2022 for severe AA, becoming the first systemic drug approved for this indication [16]. In the BRAVE-AA1 trial (N=654), 38.8% of patients on baricitinib 4 mg achieved a SALT score of 20 or below (at least 80% scalp coverage) at week 36 versus 6.2% on placebo [16].

Ritlecitinib 50 mg daily (a JAK3/TEC inhibitor) received FDA approval in June 2023 for severe AA in patients aged 12 and older. In the ALLEGRO Phase 2b/3 trial (N=718), 23.0% of patients on ritlecitinib 50 mg achieved SALT <20 at week 24 versus 1.6% on placebo (P<0.001) [17].

Telogen Effluvium: When Stress Pushes Hair into Shedding

Telogen effluvium (TE) is a diffuse, non-scarring hair shed triggered by a physiological shock that forces a large cohort of anagen hairs into the telogen (resting) phase simultaneously. Common triggers include high fever, major surgery, rapid weight loss above 10% of body mass, childbirth, and severe psychological stress. The shed typically begins 6 to 16 weeks after the trigger event, which is why many patients cannot connect the cause themselves [18].

The diagnosis requires a clinical history plus a positive hair pull test (more than 6 telogen hairs per pull from three scalp regions). Trichoscopy shows a normal follicular density with increased empty follicular openings during active shedding. Ferritin <30 ng/mL, thyroid dysfunction, and low serum zinc are the most common correctable contributors and should be checked in every new TE workup [18].

Most acute TE episodes self-resolve within 3 to 6 months. Chronic TE, defined as shedding lasting beyond 6 months, requires a thorough endocrine and nutritional assessment. Oral iron supplementation raising ferritin above 70 ng/mL is associated with reduced shedding duration in iron-deficient women, per a randomized controlled trial of 30 premenopausal women published in Acta Dermato-Venereologica [19]. No FDA-approved drug exists specifically for TE; treatment is trigger-directed.

Male Pattern Hair Loss: Genetics, DHT, and Proven Treatments

Androgenetic alopecia (AGA) in men, commonly called male pattern hair loss (MPHL), affects approximately 50% of men by age 50 [20]. The Hamilton-Norwood scale grades severity from type I (minimal recession) through type VII (only a horseshoe rim remaining). The biological driver is dihydrotestosterone (DHT), converted from testosterone by 5-alpha-reductase type II in scalp follicles. DHT binds androgen receptors in the dermal papilla and progressively miniaturizes genetically susceptible follicles [20].

Finasteride 1 mg daily inhibits 5-alpha-reductase type II, reducing scalp DHT by approximately 60% [21]. In a two-year randomized controlled trial of 1,553 men, finasteride produced a mean increase of 91 hair counts per cm² at the vertex versus a decrease of 19 in the placebo group (P<0.001) [21]. The FDA approved finasteride 1 mg (Propecia) for MPHL in 1997. Side effects including decreased libido, erectile dysfunction, and ejaculatory disorders occur in roughly 3.8% of users in controlled trials, though post-marketing reports suggest a small subset experience persistent symptoms after discontinuation [22].

Minoxidil 5% topical solution or foam (once or twice daily) is the other FDA-approved option. Its mechanism is not fully established but involves potassium channel opening, which prolongs the anagen phase and increases follicular caliber. Oral minoxidil 0.25 to 2.5 mg daily has gained widespread off-label use; a systematic review of 17 studies (N=634) found oral minoxidil produced superior hair density gains compared with topical formulations in men and women, with hypertrichosis being the most common adverse effect [23].

Platelet-rich plasma (PRP) injections deliver concentrated growth factors to the scalp. A meta-analysis of 19 randomized trials found PRP significantly increased hair density compared with placebo after three sessions, though evidence quality was rated moderate due to heterogeneous protocols [24]. The AAD 2023 hair loss guidelines note that PRP may be considered an adjunct but should not replace pharmacological first-line therapy [25].

Female Pattern Hair Loss: A Different Hormonal Picture

Female pattern hair loss (FPHL) follows the Ludwig scale (I, III), typically presenting as diffuse crown thinning that preserves the frontal hairline. FPHL affects roughly 40% of women by age 70 [26]. Androgens play a role, though many affected women have normal serum androgens. Sensitivity of the follicular androgen receptor, not just circulating DHT levels, appears to drive miniaturization in a meaningful proportion of cases [26].

Minoxidil 2% topical solution is FDA-approved for FPHL in women. Minoxidil 5% foam (approved for men) is used off-label in women with similar or slightly superior efficacy; a 48-week randomized trial comparing the two concentrations in 113 women found 5% foam produced a significantly greater increase in non-vellus hair count (P<0.05) [27]. Oral minoxidil 0.5 to 1 mg daily is increasingly used off-label in women intolerant of topical application.

Spironolactone 100 to 200 mg daily, an aldosterone antagonist with anti-androgenic properties, is used off-label for FPHL and hyperandrogenic conditions. A retrospective study of 100 women on spironolactone showed stabilization or improvement in hair density in 74% after 12 months [28]. Pregnancy must be excluded before initiation because spironolactone is a teratogen (FDA category X in pregnancy).

Finasteride is not FDA-approved for FPHL but is used off-label in post-menopausal women at 1 to 5 mg daily. A randomized trial of 137 post-menopausal women found finasteride 1 mg did not significantly outperform placebo on photographic assessment at 12 months, while higher doses (5 mg) showed modest benefits in subset analyses [29].

Monitoring and Safety: What Patients Starting Systemic Therapies Need to Know

Dupilumab's safety profile over seven years of real-world use is well characterized. Conjunctivitis occurs in 8 to 28% of AD patients on dupilumab, compared with 2 to 11% on placebo in controlled trials [4]. Twice-daily preservative-free artificial tears and topical tacrolimus 0.03% ophthalmic ointment are standard management. No immunosuppression-related infections or malignancies have been attributed causally to dupilumab at rates above background in long-term extension studies [30].

Oral JAK inhibitors carry an FDA boxed warning for serious infections, major adverse cardiovascular events (MACE), malignancy, thrombosis, and all-cause mortality. This warning was extrapolated from tofacitinib data in rheumatoid arthritis patients over 50 with cardiovascular risk factors; its direct applicability to younger AD patients on upadacitinib or abrocitinib remains debated. The AAD recommends that prescribers screen patients for active infections, tuberculosis exposure, history of malignancy, and thromboembolic risk before initiating oral JAK inhibitors, then repeat CBC, lipids, and liver function tests at 4 weeks and every 3 months thereafter [8].

For finasteride, baseline PSA in men over 40 is recommended because finasteride reduces PSA by approximately 50%, requiring a doubling correction when monitoring for prostate cancer [22]. Regular follow-up every 6 to 12 months is sufficient for stable patients on monotherapy.

Putting It Together: A Practical Clinical Pathway for Skin and Hair Patients

Patients presenting with concurrent AD and hair concerns are not rare. A 2021 JAMA Dermatology cross-sectional analysis found that 18.4% of adult AD patients reported co-occurring hair loss, with alopecia areata and telogen effluvium accounting for the majority of identified diagnoses [31].

The clinical workup should be systematic. For any new hair loss in an AD patient, thyroid-stimulating hormone, free T4, ferritin, zinc, CBC, and total testosterone (plus DHEA-S in women with signs of hyperandrogenism) are the minimum laboratory panel. Dermoscopy or trichoscopy at 20x and 70x magnification differentiates AA (yellow dots, exclamation-mark hairs), AGA (follicular miniaturization ratio above 20%), and TE (normal density, increased telogen counts) in most cases without biopsy [32].

Baricitinib 4 mg for severe AA, finasteride 1 mg for MPHL, and oral minoxidil 0.5 mg for FPHL can each be initiated alongside dupilumab without known pharmacokinetic interactions. Combining a JAK inhibitor for AA with a JAK inhibitor for AD requires physician judgment, as simultaneous systemic JAK inhibition has limited safety data in this population.

Patients with mild-to-moderate AD well controlled on topical therapy, who develop MPHL, can be assessed and managed for hair loss without disrupting their skin regimen. The two conditions share a dermatologist or telehealth prescriber, not two separate care pathways.